-transparent.png){kind=logo}
The in vitro activities of penicillin, clindamycin, chloramphenicol, metronidazole, piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin-sulbactam, cefoxitin, ceftizoxime, cefotetan, moxalactam, and imipenem against 348 Bacteroides fragilis group isolates collected from six Canadian cities during 1990 were determined by the National Committee for Clinical Laboratory Standards (NCCLS) agar dilution technique. All isolates were susceptible to chloramphenicol, metronidazole, piperacillin-tazobactam, and imipenem. For the other antibiotics tested, the following resistance rates were observed: penicillin, 97%; clindamycin, 9%; piperacillin, 19%; ticarcillin, 31%; ticarcillin-clavulanate, 0.28%; ampicillin-sulbactam, 0.85%; cefoxitin, 26%; ceftizoxime, 15%; cefotetan, 53%; and moxalactam, 17%. Susceptibility profiles to beta-lactam antibiotics varied among the different species tested: B. fragilis and Bacteroides vulgatus demonstrated lower resistance rates than Bacteroides distasonis and indole-positive Bacteroides thetaiotaomicron and Bacteroides ovatus. Ceftizoxime results should be interpreted cautiously, because the MICs obtained with the recommended NCCLS control strain were lower than expected.
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
March 1997,
International journal of antimicrobial agents,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
July 1989,
The Journal of antimicrobial chemotherapy,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
April 1980,
Antimicrobial agents and chemotherapy,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
November 1992,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
January 1992,
Clinical therapeutics,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
June 2003,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
October 1995,
Anaerobe,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
June 1990,
The Journal of antimicrobial chemotherapy,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
December 1993,
The Journal of antimicrobial chemotherapy,
A M Bourgault, and
F Lamothe, and
D J Hoban, and
M T Dalton, and
P C Kibsey, and
G Harding, and
J A Smith, and
D E Low, and
H Gilbert
May 2004,
Memorias do Instituto Oswaldo Cruz,
